NOS3 and type 2 diabetes mellitus: Clinical evidence demonstrates that PCSK9‐i preserve endothelial integrity through multimodal mechanisms: coronary vasculature: restoration of endothelial nitric oxide synthase (eNOS) activity enhances flow‐mediated dilation (35% improvement versus baseline) [61]; diabetic vasculopathy: combination therapy with glucose‐lowering agents augments endothelial progenitor cell (EPC) functionality (28% increase in EPC activity versus monotherapy) in type 2 diabetes patients [62, 63].